Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 04, 2015 5:03 AM ET


Company Overview of Sandoz Inc.

Company Overview

Sandoz Inc. develops, manufactures, markets, and distributes generic pharmaceutical products. Its therapeutic drug categories include anti-infectives, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agents, oncology therapies, respiratory therapies, alimentary tract and metabolism, blood and blood-forming organs, and antineoplastic and immunomodulating agents. The company provides oral solid generics to advanced application forms, such as transdermal patches and implants; and complex products, such as follow-on biologics (biosimilars), injectables, and inhalables. It sells its products to small and large retailers, wholesalers, hospitals, prescription b...

100 College Road West

Princeton, NJ 08540

United States

Founded in 1946





Key Executives for Sandoz Inc.

President and Head of North America
Chief Financial Officer, Head of Finance - North America and Vice President
President of Oriel Therapeutics
Vice President of Legal, IP & Compliance and General Counsel of NA
Head of Global Development Biopharmaceuticals & Oncology Injectables
Age: 61
Compensation as of Fiscal Year 2014.

Sandoz Inc. Key Developments

Sandoz Wins $67.18 Million Federal Contract

Sandoz won a $67,179,359 federal contract from the Defense Logistics Agency, Philadelphia, for potassium chloride.

Sandoz Inc. Wins $1.97 Million Federal Contract

Sandoz Inc. won a $1,973,552.50 federal contract from the U.S. Department of Veterans Affairs' National Acquisition Center, Hines, Illinois, for medical, dental and veterinary equipment and supplies.

Sandoz Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Reports Impairment Charges

Sandoz announced unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net sales were USD 2.5 billion against USD 2.41 billion a year ago. Operating income was USD 290 million against USD 276 million a year ago. Core operating income was USD 416 million against USD 373 million a year ago. For the full year, the company reported net sales were USD 9.56 billion against USD 9.16 billion a year ago. Operating income was USD 1.09 billion against USD 1.03 billion a year ago. Core operating income was USD 1.57 billion against USD 1.54 billion a year ago. Operating income increased by 6%, benefiting from strong operating performance and unrepeated prior-year legal settlements. The company reported total impairment charges of USD 18 million for the fourth quarter of 2014.

Similar Private Companies By Industry

Company Name Region
Embera NeuroTherapeutics, Inc. United States
Intervet, Inc. United States
VeroScience, LLC United States
Armstrong Pharmaceuticals, Inc. United States
Edusa Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Sandoz Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at